1. On the pharmacogenetics of non-small cell lung cancer treatment
   Mariacarmela Santarpia et al, 2016, Expert Opinion on Drug Metabolism & Toxicology CrossRef
2. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed
   Estefanía Arévalo et al, 2014, Journal of Translational Medicine CrossRef
3. Pretreatment Red Blood Cell Total Folate Concentration Is Associated With Response to Pemetrexed in Stage IV Nonsquamous Non–Small-cell Lung Cancer
   Stephen J. Bagley et al, 2017, Clinical Lung Cancer CrossRef
4. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis
   Yu Liu et al, 2013, Cancer Chemotherapy and Pharmacology CrossRef
5. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
   Paweł Krawczyk et al, 2014, Journal of Cancer Research and Clinical Oncology CrossRef
6. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum
   Wei-Yu Liao et al, 2018, Lung Cancer CrossRef
7. Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non–Small-Cell Lung Cancer
   Grace K. Dy et al, 2014, Journal of Thoracic Oncology CrossRef
8. NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status
   Grace K. Dy et al, 2014, Journal of Thoracic Oncology CrossRef
9. Pharmacogenomics of Platinum-Based Chemotherapy Sensitivity in NSCLC: Toward Precision Medicine
   Ji-Ye Yin et al, 2016, Pharmacogenomics CrossRef